SCHEMBL4769199

SCHEMBL4769199

COc1cc(-c2cc(CN3CCN(Cc4ccc(Cl)cc4)CC3)ccn2)cc(OC)c1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WNK1 Q9H4A3 1/20 0.51
TGFBR1 P36897 1/20 0.49
ACVR1 Q04771 1/20 0.49
USP2 O75604 1/20 0.48
LMNA P02545 1/20 0.48
THRB P10828 1/20 0.48
F10 P00742 1/20 0.48
ACHE P22303 1/20 0.47
BACE1 P56817 1/20 0.47
DRD2 P14416 1/20 0.47
DRD4 P21917 1/20 0.47
DRD3 P35462 1/20 0.47
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 3/20 0.46
JAK2 O60674 3/20 0.46
JAK1 P23458 3/20 0.46
TYK2 P29597 2/20 0.45
JAK3 P52333 2/20 0.45
LSS P48449 1/20 0.45
MCL1 Q07820 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4768772 0.97 TGFBR1 (0.48) WNK1TGFBR1ACVR1USP2LMNA
SCHEMBL4763764 0.93 TGFBR1 (0.49) TGFBR1ACVR1USP2LMNATHRB
SCHEMBL4773743 0.92 TGFBR1 (0.53) WNK1TGFBR1ACVR1USP2LMNA
SCHEMBL6637120 0.91 TGFBR1 (0.52) TGFBR1ACVR1USP2LMNATHRB
SCHEMBL4763699 0.91 TGFBR1 (0.51) TGFBR1ACVR1USP2LMNATHRB
SCHEMBL4772860 0.90 MAPK1 (0.49) TGFBR1ACVR1ACHEBACE1DRD2
SCHEMBL4764246 0.89 BACE1 (0.51) TGFBR1ACVR1ACHEBACE1DRD2
SCHEMBL4763891 0.89 KDM4E (0.53) TGFBR1ACVR1USP2LMNATHRB
SCHEMBL4764307 0.88 HSP90AA1 (0.57) WNK1TGFBR1ACVR1USP2LMNA
SCHEMBL7160532 0.87 KDM4E (0.51) TGFBR1ACVR1LMNAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1400513-B1 UNSYMMETRICAL CYCLIC DIAMINE COMPOUND KOWA CO (JP) 2008-01-09 EP disclosed
EP-1400513-A1 UNSYMMETRICAL CYCLIC DIAMINE COMPOUND Kowa Co., Ltd. (JP) 2004-03-24 EP disclosed
US-6552188-B2 Inhibit cell adhesion and cell infiltration; useful treating asthma, allergies, rheumatic diseases, arteriosclerosis, and inflammation; 2-(3,4,5-trimethoxyphenyl),4-((4-substituted piperazin-1-yl)methyl)pyridine compounds KOWA CO., LTD. (JP) 2003-04-22 US disclosed
US-20030022887-A1 Unsymmetrical cyclic diamine compound KOWA CO., LTD. (JP) 2003-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022887-A1 Unsymmetrical cyclic diamine compound H1-0, DDAH1, AOC1 WNK1 748/4885TGFBR1 3689/4885ACVR1 2795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.